On this page
Therapeutic action
- Antiretroviral, HIV-1 and HIV-2 nucleoside reverse transcriptase inhibitor
Indications
- HIV-1 or HIV-2 infection, in combination with other antiretroviral drugs
Forms and strengths
- 150 mg and 300 mg tablets
- 50 mg/5 ml oral solution
Dosage
- Child under 1 month: 2 mg/kg 2 times daily
- Child from 1 month to 12 years: 4 mg/kg 2 times daily
- Adult: 300 mg once daily
Weight |
10 mg/ml oral sol. |
150 mg tablet |
300 mg tablet |
---|---|---|---|
5 to 9 kg |
2.5 ml x 2 |
– |
– |
10 to 14 kg |
5 ml x 2 |
– |
– |
15 to 19 kg |
7 ml x 2 |
½ tab x 2 |
– |
20 to 24 kg |
9 ml x 2 |
½ tab x 2 |
– |
25 to 29 kg |
11 ml x 2 |
2 tab |
1 tab |
≥ 30 kg |
– |
2 tab |
1 tab |
Duration
- The duration of treatment depends on the efficacy and tolerance of lamivudine.
Contra-indications, adverse effects, precautions
- Administer with caution to patients with history of hepatic disorders.
- May cause: gastrointestinal disturbances (diarrhoea, nausea, vomiting, etc.) and possibly: haematological disorders, especially when combined with zidovudine (neutropenia, anaemia, thrombocytopenia), myopathy, hepatic or pancreatic disorders.
- Reduce dosage in patients with renal impairment.
- Pregnancy: no contra-indication
Remarks
- For prophylactic treatment to reduce mother-to-child HIV transmission, check national recommendations.
- Many fixed-dose combinations containing lamivudine are available.
Storage
Below 25 °C
Once opened, oral solution keeps for 30 days maximum.